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p= 0.047, respectively). The treatment responses and AE were significant factors in 
reducing utility values. The ratios of expected utility to disutility (= 1-utility) in PR, 
SD and PD were 0.47, 0.38, and 0.13 times lower than those of CR, respectively. The 
ratios in AEs(neutropenia, mucositis, thrombocytopenia, and anemia) were 0.45, 
0.51, 0.46, and 0.51 times lower than those of CR, respectively. CONCLUSIONS: This 
study found that patients’ quality of life was significantly deteriorated by relapsed/
refractory non-Hodgkin lymphoma. It is important to provide an appropriate treat-
ment to improve quality of life.
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OBJECTIVES: To map patient-reported EORTC QLQ-C30 scores from the ASPIRE trial 
to EQ-5D utility index scores after identifying mapping algorithms from published 
literature. ASPIRE is a randomized, open-label, phase 3 trial, which evaluated the 
safety and efficacy of carfilzomib with lenalidomide and weekly dexamethasone 
compared with lenalidomide and weekly dexamethasone in patients with relapsed 
multiple myeloma. METHODS: We searched Medline, Embase, NHSEED, CENTRAL, 
DARE (January 2008 through September 2014) and conference proceedings (2010 to 
2014) with the terms, EORTC, QLQ-C30, map, mapping, cross walk, translate, transla-
tion, algorithm, or mapping algorithm. Six articles reported mapping algorithms in a 
cancer population; relevant detailed information was available in four publications 
and extracted. Algorithms were implemented with ASPIRE data using regression 
modeling techniques including ordinary least squares (OLS) at domain and item 
levels, response mapping, and 2-part OLS model at item level where separate regres-
sions were applied for low and high average functional scale domain scores. Utility 
scores at baseline in the ASPIRE trial population were estimated with UK tariffs from 
six algorithms. RESULTS: Mean utility at baseline varied by algorithm and ranged 
from 0.59 (sd = 0.27) (Versteegh 2010, 2-part OLS model) to 0.71 (0.20) (Proskorovsky 
2014; full OLS Model). The range of scores (i.e. min, max) produced from the algo-
rithms varied considerably; as narrow as 0.06 to 1.05 (Proskorovsky 2014; full OLS 
model), and as broad as (-0.43) to 0.98 (Longworth 2014; OLS model). CONCLUSIONS: 
The mapping algorithms yielded stable average estimates and deviations. Selection 
of the better fitting model will involve congruence between modeled estimates and 
the range of utility values estimated for the UK general population (-0.594 to 1.00), 
utility scores reported elsewhere from similar subjects and clinical judgment with 
respect to patient characteristics in the ASPIRE trial.
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OBJECTIVES: To explore the degree of agreement between PRO, time –trade-off (TTO) 
utility and CROs in metastatic brain disease patients- neurocognitive function (NCF), 
Karnofsky performance status (KPS) and quality of life METHODS: We retrospec-
tively analyzed secondary data from 96 brain disease patients (57 randomized and 
39 non-randomized metastatic ) who completed tests to determine TTO utility 
with three time horizons (1, 5, and 10 years), NCF, KPS, quality of life (Functional 
Assessment of Cancer Therapy–Brain [FACT-BR]) and symptoms (MD Anderson 
Symptom Inventory–Brain Tumor [MDASI-BT]). Multiple linear regression analyses 
were used to explore the relationships between TTO utility and other outcome varia-
bles. RESULTS: The CROs significantly associated with TTO utility were the FACT-BR 
(p-value< 0.01 for 10- and 5- year TTO utility and 0.021 for 1-year TTO utility respec-
tively) and the MDASI-BT (sleep) scores (p-value = 0.045 and 0.034 for 10- and 5- year 
TTO utility respectively). However the associations found were not strong. The NCF 
and KPS scores were not significantly associated with TTO utility. CONCLUSIONS: 
None of the functional scores used in metastatic brain disease explain patients’ 
decisions to trade time for better quality of life. Quality of life scores are significant 
predictors of TTO utility, but they have only a limited impact on patients’ decisions. 
Therefore it is essential to use PROs t and incorporate patients’ perspectives of their 
symptoms and care and to complement the traditional CROs.
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OBJECTIVES: To identify a published statistical relationship suitable for pre-
dicting UK specific preference-based utility scores (EQ-5D, SF6D or HUI) from 
FACT data (FACT-BRM, FACT-G or FACT-M) in individuals with malignant mela-
noma. METHODS: A range of health and social science databases were searched 
using a keyword strategy with terms relating to the population (people with malig-
nant melanoma) and both the relevant FACT instruments (FACT-G, FACT-M, FACT-
BRM) and the generic preference-based instruments (e.g. EQ-5D, SF-6D, HUI3). 
In addition to the keyword searches, speculative searches using internet search 
engines and citation searching and reference list checking were undertaken with 
no restriction by date, language or study design. Any study which provided a 
statistical regression model describing the relationship between one (or more) 
of the stated FACT and preference-based measures in patients with malignant 
melanoma were included in the review. Identified studies were appraised using a 
checklist for the reporting standards of statistical regression models. RESULTS: 
A total of 19 studies were identified from the literature searches, increasing to 27 
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OBJECTIVES: With oral antineoplastic agents (OAAs) becoming the mainstay of 
treatment for several cancer types, understanding risk factors for medication 
non-adherence is becoming increasingly important in oncology. Patient-reported 
outcome (PRO) instruments may provide valuable insight on barriers to medica-
tion adherence in the real world. This study sought to identify and describe key 
patient-reported risk factors for non-adherence measured in observational stud-
ies evaluating adherence with OAAs. METHODS: A targeted literature review was 
conducted to identify OAA adherence studies utilizing PROs and published between 
January 2004 and December 2014. Key data abstracted from each retained article 
included study design, cancer type, and all PRO instruments or study-specific ques-
tionnaires used. Domains measured by each PRO instrument and questionnaire 
were recorded to understand patient-reported risk factors measured. RESULTS: 
Of 100 articles reviewed, 11 studies met all study inclusion/exclusion criteria. Nine 
studies (82%) used at least one validated PRO instrument and 7 studies (64%) used at 
least one study-specific questionnaire to measure patient-reported risk factors for 
non-adherence. The most commonly used PRO instruments were the Beliefs about 
Medicines Questionnaire (BMQ; n= 4) and the Satisfaction with Information about 
Medicines Scale (SIMS; n= 3). Six studies (55%) used a validated PRO to measure 
health-related quality of life (HRQL); however, only the European Organization for 
Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) 
was used in more than one study. Overall, the most common domains measured by 
PRO instruments or questionnaires were knowledge about medication (n= 7), beliefs 
about medication (n= 6), HRQL (n= 6), attitude toward disease (n= 4), symptoms (n= 3), 
and side effects (n= 3). CONCLUSIONS: Risk factors for non-adherence are com-
monly measured by patient-report in observational studies evaluating adherence 
with OAAs. Further work is needed to clarify advantages and disadvantages of 
using specific PROs to measure relevant risk factors and determine if risk factors 
vary by cancer type.
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OBJECTIVES: To elicit health utilities for refractory or relapsed peripheral T-cell 
lymphoma (PTCL) using visual analog scaling (VAS) and time trade-off (TTO) meth-
ods, to examine the impact of age on TTO values, and to estimate power curves to 
convert VAS scores to TTO values. METHODS: Health state vignettes for four health 
states (complete remission, partial response, stable disease and progressive disease) 
and four treatment-related adverse events (mucositis, thrombocytopenia, anemia, 
neutropenia) were developed. Utility elicitation from 125 Koreans from the general 
public living in Seoul was conducted using VAS and TTO methods. Linear mixed 
regression and generalized linear mixed models were used to assess the impact 
of age on TTO values. Nonlinear regression was used to estimate power curves to 
convert VAS scores to TTO values. RESULTS: Complete remission was the most pre-
ferred health state (mean TTO value: 0.885), followed by partial response, 0.784; sta-
ble disease, 0.746; and progressive disease, 0.567. Treatment related adverse events 
were related to significant negative impacts. The smallest disutility was associated 
with mucositis (mean TTO disutility: -0.075). The largest disutility was related to 
neutropenia (mean TTO disutility: -0.107). Age was not a significant determinant 
of utility values. Health state (p-value < 0.001) and cancer experience (p-value = 
0.025) had a significant impact on preferences. Two power functions ( , were derived, 
where u = aggregated TTO values and v = aggregated VAS score. CONCLUSIONS: 
This study demonstrated that utility values and power curves for PTCL can be used 
in economic evaluations and decision making.
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OBJECTIVES: To elicit utility values for health states associated with relapsed/refrac-
tory non-Hodgkin lymphoma and compare utilities after adjusting for demographic 
and societal characteristics in South Korea’s general public. METHODS: Health state 
‘vignettes’ associated with a treatment for R/R non-Hodgkin lymphoma were devel-
oped and characterized as: complete response(CR), partial response(PR), stable(SD), 
progressive disease(PD), and treatment related adverse events(neutropenia, mucosi-
tis, thrombocytopenia, anemia; AE). Vignettes were valued by South Koreans 
using the time trade-off method. The health state vignettes combined informa-
tion gathered from sources such as published literature, consultations with clini-
cal specialists, and interviews with patients, which were used to develop health 
dimensions consistent with the EQ-5D. Utility values were summarized and com-
pared by characteristics of interviewees. The influencing factors of utility values 
were estimated using mixed Beta regressions. Since the utility values for various 
health states were measured by a subject, subjects were used as a strata. The glim-
mix SAS procedure was used to determine factors influencing utility. RESULTS: 
A total 166 Korean were interviewed. The subjects were aged 46(±10.6) years old 
with a near even gender split. Mean utilities were CR;0.89(±0.08), PR;0.79(±0.13), 
SD;0.75(±0.12), PD;0.45(±0.16), AE-neutropenia;0.70(±0.17), AE-mucositis;0.79(±014), 
AE-thrombocytopenia;0.77(±0.14), and AE-anemia;0.79(±0.13). Utility values for 
PR and PD were significantly different between males and females (p= 0.0135 and 
